(18) reviewed four generations of chimeric antigen receptor T (CAR-T) cell therapy in lung cancer, highlighting key targets including EGFR, EphA2, MUC1, and HER2, along with associated toxicities. The gene discussed is EGFR; the disease is lung carcinoma.